Compare prices and buy Tesamorelin from 46 research peptide vendors - also called suppliers or sources. Updated daily.
A 44-amino-acid synthetic GHRH analog (CAS 218949-48-5) with an N-terminal trans-3-hexenoyl moiety that resisted DPP-4 cleavage and slowed plasma degradation relative to native GHRH in the developer's nonclinical studies. Agonizes the GHRH receptor to stimulate the pituitary's own pulsatile GH release, which raises IGF-1. FDA-approved by Theratechnologies as Egrifta, with current labels for Egrifta SV and Egrifta WR, for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and the only GHRH analog holding a current US approval.
For research purposes only. Not medical advice.
Tesamorelin (development code TH9507) is a synthetic 44-amino-acid analog of human growth-hormone-releasing hormone, GHRH(1-44). It carries an N-terminal trans-3-hexenoyl group. In the developer's nonclinical studies, published in 2007, that group made the peptide resistant to the enzyme DPP-4 and slowed its breakdown in plasma compared with native GHRH. In healthy subjects, the Egrifta SV and Egrifta WR labels report mean elimination half-lives of 8 and 11 minutes. By binding the GHRH receptor on the pituitary, it stimulates the gland's own pulsatile secretion of growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1).
This "secretagogue" approach, which prompts the body to release its own growth hormone, is shared in principle with several other peptides in the growth-hormone category, but the receptors differ. Tesamorelin, sermorelin, and CJC-1295 act at the GHRH receptor, whereas ipamorelin acts at the separate ghrelin / GH-secretagogue receptor. Sermorelin corresponds to the shorter GHRH(1-29) fragment, while tesamorelin retains the full 44-residue sequence with its stabilizing modification. Tesamorelin vs sermorelin vs ipamorelin compares the three compounds' receptors, trial records and approval histories.
Tesamorelin's pivotal evidence comes from Phase 3 trials in HIV-associated lipodystrophy, a condition in which long-term antiretroviral therapy is associated with accumulation of excess visceral (abdominal) fat. The two placebo-controlled trials randomized 816 patients, 412 in the first (protocol TH9507/III/LIPO/010) and 404 in the second. Reporting the first trial in the New England Journal of Medicine in 2007, Falutz and colleagues found that visceral adipose tissue, measured by CT scan, fell 15.2% over 26 weeks with tesamorelin and rose 5.0% with placebo. The Egrifta labels analyze the same trial in the intent-to-treat population, carrying the last observation forward, and report an 18% fall against a 2% rise, a mean difference from placebo of 20%. For the second trial the labels report a mean difference of 12%.
Tesamorelin was approved by the FDA in November 2010 under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Sermorelin, the other GHRH analog the FDA approved, was sold as Geref until the FDA withdrew both approvals in 2009, so tesamorelin is the only GHRH analog holding a current US approval. A single-vial formulation, Egrifta SV, followed, and on March 25, 2025 the FDA approved a further formulation, Egrifta WR (tesamorelin F8), for the same indication. Egrifta SV is mixed with sterile water and used immediately, while Egrifta WR is mixed with bacteriostatic water and its label says to discard the solution 7 days after mixing. The WR label states that the two products are not substitutable.
Both current labels state that the product is not indicated for weight loss management and that its long-term cardiovascular safety has not been established. Because tesamorelin holds a current approval, the 503A bulks-list and Category 2 process is not where its status is decided, and it appears in neither table of the FDA's Category 2 page as of October 21, 2026. Its 44 residues exceed the 40-amino-acid line in the FDA's definition of a protein, and Drugs@FDA records that its application was deemed a biologics license on March 23, 2020.
Compared with the GLP-1 category, tesamorelin has relatively few vendor aliases. It is listed plainly as "Tesamorelin" or the shorthand "Tesa," and occasionally misspelled "Tesamorlin." Vendors also sell it premixed with ipamorelin, a ghrelin-receptor agonist, as a tesamorelin + ipamorelin blend that is indexed separately. PeptideScouter indexes tesamorelin on a per-milligram basis and confirms identity against its molecular formula (C221H366N72O67S, CAS 218949-48-5) rather than the product title. The Egrifta labels state vial contents as tesamorelin free base, with the acetate salt about a tenth heavier, so a listing's milligram figure matches the label's basis only when it says which form it counts.
Yes. Tesamorelin was approved by the FDA in 2010 as Egrifta (Theratechnologies) for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and its current products are Egrifta SV and Egrifta WR. Both labels state that the product is not indicated for weight loss management. Sermorelin, the other GHRH analog the FDA approved, was sold as Geref until both approvals were withdrawn in 2009, so tesamorelin is the only GHRH analog holding a current US approval. The material sold by research peptide vendors is research-grade, offered for laboratory research use only and not as the approved drug or for human consumption.
Tesamorelin, sermorelin, and CJC-1295 are all GHRH-receptor agonists that prompt the pituitary to release growth hormone. Sermorelin is the shorter GHRH(1-29) fragment, tesamorelin is a stabilized full-length GHRH(1-44) analog, and CJC-1295 adds a half-life-extending modification. Ipamorelin works through a different receptor entirely (the ghrelin / GH-secretagogue receptor). The distinction is mechanistic.
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone with an N-terminal trans-3-hexenoyl group that, in the developer's nonclinical studies, made it resistant to DPP-4 breakdown. It binds the GHRH receptor on the pituitary and stimulates the body's own pulsatile release of growth hormone, which raises IGF-1. This is a secretagogue mechanism, as opposed to administering growth hormone directly.
No. Egrifta SV and Egrifta WR are the FDA-approved products, each with its own labeled formulation, and the approval covers those products only, not research-grade tesamorelin. Research peptide vendors sell tesamorelin for laboratory research use only, not as the approved drug or for human consumption. PeptideScouter tracks tesamorelin listings on a per-milligram basis and verifies each against the compound's CAS and molecular formula.
Tesamorelin is sold by 46 research peptide vendors indexed on PeptideScouter, with 104 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 46 indexed research peptide vendors currently have Tesamorelin in stock. Stock state is refreshed daily from each vendor's catalog.
Renova Peptides currently lists Tesamorelin at $2.60/mg, the lowest listed price across 46 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.34/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. 45 of the 46 vendors listing Tesamorelin publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $2.60/mg listed to $2.34/mg at Renova Peptides. Each vendor's code is shown beside its price in the table above.
Tesamorelin ranges from $2.60/mg to $24.50/mg across 104 listings from 46 research peptide vendors, normalized to USD per milligram and refreshed daily.
46 research peptide vendors currently list Tesamorelin on PeptideScouter. We track 104 listings across size and kit variants.
Tesamorelin's CAS Registry Number is 218949-48-5. It is also sold as Tesa, Tesamorlin, ZC-Tesa.
